ANI Pharmaceuticals Yönetim

Yönetim kriter kontrolleri 3/4

ANI Pharmaceuticals CEO'su Nikhil Lalwani, Sep2020 tarihinde atandı, in görev süresi 4.17 yıldır. in toplam yıllık tazminatı $ 8.08M olup, şirket hissesi ve opsiyonları dahil olmak üzere 9.5% maaş ve 90.5% ikramiyelerden oluşmaktadır. şirketin hisselerinin 1.92% ine doğrudan sahiptir ve bu hisseler $ 21.43M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 3 yıl ve 4.2 yıldır.

Anahtar bilgiler

Nikhil Lalwani

İcra Kurulu Başkanı

US$8.1m

Toplam tazminat

CEO maaş yüzdesi	9.5%
CEO görev süresi	4.2yrs
CEO sahipliği	1.9%
Yönetim ortalama görev süresi	3yrs
Yönetim Kurulu ortalama görev süresi	4.2yrs

Son yönetim güncellemeleri

Recent updates

ANI Pharmaceuticals: Tezruly Just Approved, 2 More NDAs Under Review And Alimera Science Acquisition Could Triple Revenue By 2028

Aug 02

Subdued Growth No Barrier To ANI Pharmaceuticals, Inc.'s (NASDAQ:ANIP) Price

Jun 10

ANI Pharmaceuticals Is Undervalued, As Royalty Potential Is Overlooked

Jun 10

These 4 Measures Indicate That ANI Pharmaceuticals (NASDAQ:ANIP) Is Using Debt Reasonably Well

Feb 17

Additional Considerations Required While Assessing ANI Pharmaceuticals' (NASDAQ:ANIP) Strong Earnings

Nov 15

Does ANI Pharmaceuticals (NASDAQ:ANIP) Have A Healthy Balance Sheet?

Sep 22

Does ANI Pharmaceuticals (NASDAQ:ANIP) Have A Healthy Balance Sheet?

Feb 22

We Think ANI Pharmaceuticals (NASDAQ:ANIP) Has A Fair Chunk Of Debt

Oct 28

ANI Pharma launches generic Prochlorperazine maleate tablets

Aug 29

ANI Pharmaceuticals' generic dexamethasone tablets get FDA approval

Aug 16

ANI Pharmaceuticals Q2 2022 Earnings Preview

Aug 05

CEO Tazminat Analizi

Nikhil Lalwani'un ücretlendirmesi ANI Pharmaceuticals'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	US$23m
Mar 31 2024	n/a	n/a	US$31m
Dec 31 2023	US$8m	US$764k	US$15m
Sep 30 2023	n/a	n/a	US$10m
Jun 30 2023	n/a	n/a	-US$8m
Mar 31 2023	n/a	n/a	-US$28m
Dec 31 2022	US$5m	US$737k	-US$50m
Sep 30 2022	n/a	n/a	-US$69m
Jun 30 2022	n/a	n/a	-US$65m
Mar 31 2022	n/a	n/a	-US$63m
Dec 31 2021	US$7m	US$715k	-US$43m
Sep 30 2021	n/a	n/a	-US$22m
Jun 30 2021	n/a	n/a	-US$17m
Mar 31 2021	n/a	n/a	-US$15m
Dec 31 2020	US$4m	US$199k	-US$23m

Tazminat ve Piyasa: Nikhil 'nin toplam tazminatı ($USD 8.08M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 3.21M ).

Tazminat ve Kazançlar: Nikhil 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Nikhil Lalwani (46 yo)

4.2yrs

Görev süresi

US$8,078,353

Tazminat

Mr. Nikhil Lalwani served as a Director of Association for Accessible Medicines. He served as the Chief Executive Officer of InvaGen Pharmaceuticals, Inc. since October 24, 2016. Mr. Lalwani is a seasoned...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Nikhil Lalwani	President	4.2yrs	US$8.08m	1.92% $ 21.4m
Stephen Carey	Senior VP of Finance & CFO	8.5yrs	US$2.58m	0.83% $ 9.3m
Chad Gassert	Senior Vice President of Corporate Development & Strategy	3yrs	US$1.90m	1.24% $ 13.9m
Christopher Mutz	Senior Vp & Head of Rare Disease	3.8yrs	US$1.91m	0.43% $ 4.8m
Ori Gutwerg	Senior Vice President of Generics	3.8yrs	US$1.94m	0.40% $ 4.4m
Muthusamy Shanmugam	Head of R&D	3yrs	Veri yok	0.26% $ 2.9m
James Marken	Senior Vice President of Operations	8.5yrs	US$1.43m	0.60% $ 6.8m
Elizabeth Powell	Chief Compliance Officer & Head of Legal of Rare Disease	2.8yrs	Veri yok	Veri yok
Meredith Cook	Senior VP	2.3yrs	Veri yok	0.29% $ 3.2m
Krista Davis	Senior VP & Chief Human Resources Officer	2.2yrs	Veri yok	0.26% $ 2.9m
Mary Pao	Chief Medical Officer	2.8yrs	Veri yok	Veri yok
Thomas Rowland	Senior VP & Head of Established Brands	3yrs	Veri yok	0.17% $ 2.0m

3.0yrs

Ortalama Görev Süresi

51.5yo

Ortalama Yaş

Deneyimli Yönetim: ANIP 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Nikhil Lalwani	President	4.2yrs	US$8.08m	1.92% $ 21.4m
Muthusamy Shanmugam	Head of R&D	3yrs	Veri yok	0.26% $ 2.9m
Patrick Walsh	Independent Chairman	6.5yrs	US$422.21k	0.38% $ 4.3m
Antonio Pera	Independent Director	4.3yrs	US$393.25k	0.16% $ 1.8m
Thomas Haughey	Independent Director	6.5yrs	US$412.21k	0.26% $ 3.0m
Jeanne Thoma	Independent Director	4.3yrs	US$395.75k	0.21% $ 2.3m
Renee Tannenbaum	Independent Director	2.7yrs	US$392.37k	0.12% $ 1.3m
Matthew Leonard	Independent Director	1.3yrs	US$470.76k	0.061% $ 687.4k

4.2yrs

Ortalama Görev Süresi

61.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: ANIP 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4.2 yıldır).

ANI Pharmaceuticals Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

Head of R&D notifies of intention to sell stock

President recently sold US$1.1m worth of stock

President notifies of intention to sell stock

Head of R&D notifies of intention to sell stock

ANI Pharmaceuticals, Inc., Annual General Meeting, May 21, 2024

Independent Director notifies of intention to sell stock

Recent updates

ANI Pharmaceuticals Is Acting Like It Is Being Acquired

ANI Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 08, 2024

ANI Pharmaceuticals, Inc. Announces the FDA Approval and Launch of Estradiol Gel, 0.06%

ANI Pharmaceuticals: A Rare GARP Stock In An Overbought Market

ANI Pharmaceuticals, Inc. (NasdaqGM:ANIP) completed the acquisition of Alimera Sciences, Inc. (NasdaqGM:ALIM) from Caligan Partners Master Fund LP and Caligan Partners Master Fund LP, managed by Caligan Partners, LP and others.

Alimera Sciences, Inc. Takes Legal Action Against ANI Pharmaceuticals, Inc. to Enforce Merger Agreement

Alimera Sciences, Inc. Takes Legal Action Against ANI Pharmaceuticals, Inc. to Enforce Merger Agreement

There's No Escaping ANI Pharmaceuticals, Inc.'s (NASDAQ:ANIP) Muted Revenues

ANI Pharmaceuticals' (NASDAQ:ANIP) Earnings Are Weaker Than They Seem

Is ANI Pharmaceuticals (NASDAQ:ANIP) Using Too Much Debt?

ANI Pharmaceuticals, Inc. Revises Earnings Guidance for the Year 2024

ANI Pharmaceuticals: Tezruly Just Approved, 2 More NDAs Under Review And Alimera Science Acquisition Could Triple Revenue By 2028

ANI Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 06, 2024

ANI Pharmaceuticals, Inc. Announces the FDA Approval and Launch of L-Glutamine Oral Powder

ANI Pharmaceuticals, Inc.(NasdaqGM:ANIP) dropped from Russell 3000E Value Index

ANI Pharmaceuticals Announces the FDA Approval and Launch of Naproxen Delayed-Release Tablets, USP

ANI Pharmaceuticals, Inc. (NasdaqGM:ANIP) signed a definitive agreement to acquire Alimera Sciences, Inc. (NasdaqGM:ALIM) from Caligan Partners Master Fund LP and Caligan Partners Master Fund LP, managed by Caligan Partners, LP and others for approximately $300 million.

Subdued Growth No Barrier To ANI Pharmaceuticals, Inc.'s (NASDAQ:ANIP) Price

ANI Pharmaceuticals Is Undervalued, As Royalty Potential Is Overlooked

Head of R&D notifies of intention to sell stock

President recently sold US$1.1m worth of stock

President notifies of intention to sell stock

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

ANI Pharmaceuticals, Inc. Reiterates Earnings Guidance for the Full Year 2024

ANI Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 10, 2024

Head of R&D notifies of intention to sell stock

ANI Pharmaceuticals, Inc. Announces the Launch of Baclofen Oral Suspension

ANI Pharmaceuticals, Inc., Annual General Meeting, May 21, 2024

ANI Pharmaceuticals, Inc. Announces the Launch of Levofloxacin Oral Solution, USP

Consensus EPS estimates increase by 27%

Independent Director notifies of intention to sell stock

Price target increased by 7.5% to US$75.50

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

ANI Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2024

These 4 Measures Indicate That ANI Pharmaceuticals (NASDAQ:ANIP) Is Using Debt Reasonably Well

ANI Pharmaceuticals, Inc. to Report Second Half, 2023 Results on Feb 29, 2024

ANI Pharmaceuticals Announces the Launch of Pentoxifylline Extended-Release Tablets, USP

Head of R&D notifies of intention to sell stock

ANI Pharmaceuticals, Inc. Announces the FDA Approval and Launch of Indomethacin Oral Suspension, USP

Head of R&D notifies of intention to sell stock

Head of R&D notifies of intention to sell stock

Additional Considerations Required While Assessing ANI Pharmaceuticals' (NASDAQ:ANIP) Strong Earnings

Head of Rare Disease recently sold US$157k worth of stock

New minor risk - Earnings quality

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

ANI Pharmaceuticals, Inc. Revises Earnings Guidance for the Year 2023

New major risk - Revenue and earnings growth

ANI Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 08, 2023

Head of R&D notifies of intention to sell stock

Ani Pharmaceuticals Announces Fda Approval and Commercial Availability of New 1-Ml Vial Size of Purified Cortrophin®? Gel, Appropriate for Adjunctive Treatment of Certain Patients with Acute Gouty Arthritis Flares

Does ANI Pharmaceuticals (NASDAQ:ANIP) Have A Healthy Balance Sheet?

Head of R&D notifies of intention to sell stock

Ani Pharmaceuticals Announces the Fda Approval and Launch of Estradiol Gel, 0.1%

ANI Pharmaceuticals, Inc. Announces Board Changes

Head of R&D notifies of intention to sell stock

President recently sold US$3.3m worth of stock

President notifies of intention to sell stock

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

ANI Pharmaceuticals, Inc. Revises Earnings Guidance for the Full Year 2023

ANI Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 09, 2023

New minor risk - Profitability

Head of R&D notifies of intention to sell stock

Price target increased by 12% to US$55.00

Head of R&D notifies of intention to sell stock

ANI Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $75.000033 million.

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

ANI Pharmaceuticals, Inc. Raises Revenue Guidance for Full Year 2023

Consensus EPS estimates fall by 42%, revenue upgraded

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind